- Home
- BWAY vs INZY Comparison
BWAY vs INZY Comparison
Compare BWAY & INZY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BWAY
- INZY
- Stock Information
- Founded
- BWAY 2003
- INZY 2015
- Country
- BWAY Israel
- INZY United States
- Employees
- BWAY N/A
- INZY N/A
- Industry
- BWAY Medical/Dental Instruments
- INZY Biotechnology: Pharmaceutical Preparations
- Sector
- BWAY Health Care
- INZY Health Care
- Exchange
- BWAY Nasdaq
- INZY Nasdaq
- Market Cap
- BWAY 207.4M
- INZY 188.2M
- IPO Year
- BWAY 2019
- INZY 2020
- Fundamental
- Price
- BWAY $10.38
- INZY $1.00
- Analyst Decision
- BWAY Strong Buy
- INZY Strong Buy
- Analyst Count
- BWAY 3
- INZY 10
- Target Price
- BWAY $13.17
- INZY $16.90
- AVG Volume (30 Days)
- BWAY 93.8K
- INZY 548.7K
- Earning Date
- BWAY 03-11-2025
- INZY 03-10-2025
- Dividend Yield
- BWAY N/A
- INZY N/A
- EPS Growth
- BWAY N/A
- INZY N/A
- EPS
- BWAY 0.09
- INZY N/A
- Revenue
- BWAY $41,016,000.00
- INZY N/A
- Revenue This Year
- BWAY $349.63
- INZY N/A
- Revenue Next Year
- BWAY $27.16
- INZY N/A
- P/E Ratio
- BWAY $62.47
- INZY N/A
- Revenue Growth
- BWAY 29.04
- INZY N/A
- 52 Week Low
- BWAY $4.61
- INZY $0.98
- 52 Week High
- BWAY $11.79
- INZY $7.80
- Technical
- Relative Strength Index (RSI)
- BWAY 52.06
- INZY 33.60
- Support Level
- BWAY $8.88
- INZY $0.98
- Resistance Level
- BWAY $10.54
- INZY $1.10
- Average True Range (ATR)
- BWAY 0.55
- INZY 0.10
- MACD
- BWAY 0.03
- INZY 0.02
- Stochastic Oscillator
- BWAY 66.39
- INZY 32.81
About BWAY BrainsWay Ltd.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.
About INZY Inozyme Pharma Inc.
Inozyme Pharma Incclinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. The company is pursuing the development of therapeutics to address the underlying causes of these debilitating diseases. The company is focused on developing a novel therapy to treat the rare genetic diseases of ENPP1 and ABCC6 Deficiencies. The company product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to correct a defect in a pathway involving ENPP1 and ABCC6 Deficiencies.